MICROBIX BIOSYSTEMS INC (MBX.CA) Fundamental Analysis & Valuation

TSX:MBX • CA59501P1045

Current stock price

0.24 CAD
0 (0%)
Last:

This MBX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. MBX.CA Profitability Analysis

1.1 Basic Checks

  • MBX had negative earnings in the past year.
  • MBX had a negative operating cash flow in the past year.
  • In multiple years MBX reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.
MBX.CA Yearly Net Income VS EBIT VS OCF VS FCFMBX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M 4M -4M -6M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -11.67%, MBX belongs to the top of the industry, outperforming 82.61% of the companies in the same industry.
  • The Return On Equity of MBX (-16.05%) is better than 82.61% of its industry peers.
Industry RankSector Rank
ROA -11.67%
ROE -16.05%
ROIC N/A
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
MBX.CA Yearly ROA, ROE, ROICMBX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • MBX's Gross Margin of 46.74% is fine compared to the rest of the industry. MBX outperforms 78.26% of its industry peers.
  • MBX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
MBX.CA Yearly Profit, Operating, Gross MarginsMBX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MBX.CA Health Analysis

2.1 Basic Checks

  • MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MBX has more shares outstanding
  • MBX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, MBX has a worse debt to assets ratio.
MBX.CA Yearly Shares OutstandingMBX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MBX.CA Yearly Total Debt VS Total AssetsMBX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • MBX has an Altman-Z score of 1.38. This is a bad value and indicates that MBX is not financially healthy and even has some risk of bankruptcy.
  • MBX has a better Altman-Z score (1.38) than 65.22% of its industry peers.
  • A Debt/Equity ratio of 0.25 indicates that MBX is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.25, MBX perfoms like the industry average, outperforming 56.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.38
ROIC/WACCN/A
WACC8.42%
MBX.CA Yearly LT Debt VS Equity VS FCFMBX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

  • A Current Ratio of 7.51 indicates that MBX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 7.51, MBX belongs to the top of the industry, outperforming 86.96% of the companies in the same industry.
  • MBX has a Quick Ratio of 4.48. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
  • MBX has a Quick ratio of 4.48. This is amongst the best in the industry. MBX outperforms 82.61% of its industry peers.
Industry RankSector Rank
Current Ratio 7.51
Quick Ratio 4.48
MBX.CA Yearly Current Assets VS Current LiabilitesMBX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. MBX.CA Growth Analysis

3.1 Past

  • The earnings per share for MBX have decreased strongly by -320.71% in the last year.
  • Looking at the last year, MBX shows a very negative growth in Revenue. The Revenue has decreased by -27.23% in the last year.
  • The Revenue has been growing by 12.05% on average over the past years. This is quite good.
EPS 1Y (TTM)-320.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-233.33%
Revenue 1Y (TTM)-27.23%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-30.2%

3.2 Future

  • MBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.75% yearly.
  • Based on estimates for the next years, MBX will show a very strong growth in Revenue. The Revenue will grow by 29.96% on average per year.
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MBX.CA Yearly Revenue VS EstimatesMBX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
MBX.CA Yearly EPS VS EstimatesMBX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.02 -0.02 0.04 0.06

More info and screens

Find the best growth stocksShow best growing peers

4

4. MBX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 3.39, which indicates a rather cheap valuation of MBX.
  • MBX's Price/Forward Earnings ratio is rather cheap when compared to the industry. MBX is cheaper than 95.65% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 38.50. MBX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 3.39
MBX.CA Price Earnings VS Forward Price EarningsMBX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX.CA Per share dataMBX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MBX's earnings are expected to grow with 52.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.75%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MBX.CA Dividend Analysis

5.1 Amount

  • MBX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MBX.CA Fundamentals: All Metrics, Ratios and Statistics

MICROBIX BIOSYSTEMS INC

TSX:MBX (4/17/2026, 7:00:00 PM)

0.24

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-14
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.88%
Ins Owner ChangeN/A
Market Cap33.12M
Revenue(TTM)16.76M
Net Income(TTM)-4.27M
Analysts80
Price Target0.51 (112.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.39
P/S 1.98
P/FCF N/A
P/OCF N/A
P/B 1.24
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)0.07
Fwd EY29.46%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.12
BVpS0.19
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -11.67%
ROE -16.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.74%
FCFM N/A
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.46%
Cap/Sales 4.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.51
Quick Ratio 4.48
Altman-Z 1.38
F-Score2
WACC8.42%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)119.48%
Cap/Sales(3y)5.99%
Cap/Sales(5y)7.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-320.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-233.33%
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-27.23%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-30.2%
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-242.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-13227.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-462.4%
OCF growth 3YN/A
OCF growth 5YN/A

MICROBIX BIOSYSTEMS INC / MBX.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.


What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a valuation rating of 4 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.


How profitable is MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.


Can you provide the financial health for MBX stock?

The financial health rating of MICROBIX BIOSYSTEMS INC (MBX.CA) is 5 / 10.